|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Depression Therapy Area Pipeline Report
|
Mar 2011 |
£945 |
100% |
Depression Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Oct 2011 |
£2,215 |
99% |
Major Depressive Disorder (MDD) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Oct 2011 |
£2,215 |
98% |
Psychopharmacotherapy Market Insights
Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012
|
Nov 2005 |
£795 |
96% |
Forecast Insight: Depression
High rewards for novel and adjunctive therapies in treatment-resistant depression
|
Dec 2010 |
£9,615 |
96% |
Central Nervous System Disorders Therapeutics Market to 2017
Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half The Market Value in 2010
|
Nov 2011 |
£2,215 |
89% |
|
Antiageing and Life Enhancement Pharmacotherapeutics
|
Jan 2006 |
£795 |
87% |
Endpoints - Clinical Trials in CNS Disorders
Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
|
Nov 2011 |
£2,215 |
86% |
|
St. Jude Medical Inc. Product Pipeline Analysis
|
Jan 2009 |
£475 |
85% |
Bipolar Disorder Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Nov 2011 |
£2,215 |
81% |
Comparative Analysis of Late Stage Pipeline Molecules in Major Indications
Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
|
Jul 2011 |
£2,215 |
81% |
|
Northstar Neuroscience, Inc. Product Pipeline Analysis
|
Jan 2009 |
£475 |
80% |
|
Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022
|
Oct 2007 |
£1,499 |
80% |
|
Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
|
Jan 2011 |
£680 |
79% |
|
Markets for Emerging Pharmaceutical Technologies
|
Mar 2011 |
£3,065 |
77% |
|
The Antipsychotics Market Insight & Analysis 2008
|
Feb 2008 |
£1,499 |
74% |
Blood-Brain Barrier
Bridging Options for Drug Discovery and Development
|
May 2008 |
£710 |
74% |
|
Cyberonics, Inc. Product Pipeline Analysis
|
Jan 2009 |
£475 |
72% |
Duloxetine: Core Country Coverage
Pipeline Selector
|
Jun 2011 |
£250 |
69% |
Commercial Insight: Antipsychotics
Revenues of depots and new agents will partially offset generic erosion
|
Oct 2009 |
£9,615 |
67% |
Neuromodulation Devices: World Market Prospects
2011-2021
|
Oct 2011 |
£1,699 |
66% |
Desvenlafaxine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Mirtazapine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Venlafaxine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Fluvoxamine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Reboxetine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Milnacipran - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Citalopram - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Bupropion - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
Paroxetine - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
65% |
